Targeting Programmed Cell Death 1 in Ovarian Cancer

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 3987-3989

  Homicsko, Krisztian ^a,b,c   Coukos, George ^a,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE CONTROL; EDITORIAL; EXOME; FEMALE; GENE ACTIVATION; HOMOLOGOUS RECOMBINATION; HUMAN; MICROENVIRONMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; OVARIAN NEOPLASMS; SALVAGE THERAPY; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SALVAGE THERAPY;

EID: 84951825543     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.7785     Document Type: Editorial

References (37)

1. Hanahan D, Coussens LM: Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309-322, 2012
2. Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213, 2003
3. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004
4. Sato E, Olson SH, Ahn J, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543, 2005
5. Cho H, Hur HW, Kim SW, et al: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15-23, 2009
6. Zhang M, He Y, Sun X, et al: A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res 7:19, 2013
7. Hwang W-T, Adams SF, Tahirovic E, et al: Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol Oncol 124:192-198, 2012
8. Ramakrishna V, Ross MM, Petersson M, et al: Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15:751-763, 2003
9. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107:7875-7880, 2010
10. Abiko K, Mandai M, Hamanishi J, et al: PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19:1363-1374, 2013
11. Liu Y, Zeng B, Zhang Z, et al: B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol 129:471-481, 2008
12. Curiel TJ, Wei S, Dong H, et al: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562-567, 2003
13. Hamanishi J, Mandai M, Iwasaki M, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360-3365, 2007
14. Duraiswamy J, Freeman GJ, Coukos G: Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 73:6900-6912, 2013
15. Brahmer JR, Tykodi SS, Chow LQM, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
16. Hamanishi J, Mandai M, Ikeda T, et al: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015-4022, 2015
17. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
18. Duraiswamy J, Freeman GJ, Coukos G: Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors-response. Cancer Res 74:633-635, 2014
19. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014
20. Champiat S, Ferté C, Lebel-Binay S, et al: Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 3:e27817, 2014
21. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
22. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med 372:2509-2520, 2015
23. Birkbak NJ, Kochupurakkal B, Izarzugaza JMG, et al: Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One 8:e80023, 2013
24. Stavropoulou AV, Fostira F, Pertesi M, et al: Prevalence of BRCA1 mutations in familial and sporadic Greek ovarian cancer cases. PLoS One 8:e58182, 2013
25. Turner N, Tutt A, Ashworth A: Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
26. Hansmann T, Pliushch G, Leubner M, et al: Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet 21:4669-4679, 2012
27. Mukhopadhyay A, Plummer ER, Elattar A, et al: Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum, and survival. Cancer Res 72:5675-5682, 2012
28. George J, Alsop K, Etemadmoghadam D, et al: Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 19:3474-3484, 2013
29. McAlpine JN, Porter H, Köbel M, et al: BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 25:740-750, 2012
30. Rabinovich A, Medina L, Piura B, et al: Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21:122-128, 2010
31. Harvey HA, Allegra JC, Demers LM, et al: Immunosuppression and human cancer: Role of prostaglandins. Cancer 39:2362-2364, 1977
32. Pickup M, Novitskiy S, Moses HL: The roles of TGF-β in the tumour microenvironment. Nat Rev Cancer 13:788-799, 2013
33. Ino K: Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr Opin Obstet Gynecol 23:13-18, 2011
34. Bak SP, Alonso A, Turk MJ, et al: Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol 46:258-268, 2008
35. Tothill RW, Tinker AV, George J, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198-5208, 2008
36. Motz GT, Santoro SP, Wang L-P, et al: Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607-615, 2014
37. Buckanovich RJ, Facciabene A, Kim S, et al: Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14:28-36, 2007